BiondVax Pharmaceuticals Ltd. recently reported the company's relocation to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel.
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.